A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RDEA3170 in Healthy Male Japanese Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Verinurad (Primary)
- Indications Gout
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ardea Biosciences
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 08 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jun 2013 New trial record